Introduction: Today marks the final bidding day for the highly anticipated Mukka Proteins IPO. With the issue being oversubscribed a remarkable 136.89 times so far, it's evident that investor interest has been fervent. Led by Non-Institutional Investors (NIIs) and retail investors, this IPO has garnered significant attention in the market. As we approach the closure of the bidding process, let's delve into what this means for potential investors and how the Grey Market Premium (GMP) reflects market sentiment.
The Mukka Proteins initial public offering (IPO) commenced for subscription on Thursday, February 29. Those who are interested in subscribing have until today, Monday, March 4, to apply for the issue. During the first two days of its launch, Mukka Proteins IPO garnered positive feedback. According to information available on the BSE, the Mukka Proteins IPO was subscribed 6.97 times on day two, and 2.47 times on day one.
Fish meal, fish oil, and fish soluble paste are produced and sold by Mukka Proteins Ltd. These products are essential to the creation of aqua feed (for fish and prawns), chicken feed (for grilling and layering), and pet food (chow for dogs and cats).
The price range for Mukka Proteins' initial public offering (IPO) is ₹26 to ₹28 per equity share with a face value of Re 1. The 535 equity shares that make up each IPO lot for Mukka Proteins are followed by multiples of 535 equity shares.
Status of Mukka Proteins' IPO subscription
Investor demand for Mukka Proteins' initial public offering (IPO) is still very high on day three. As of 17:18 IST, the total number of subscriptions to the Mukka Proteins IPO has been 136.89, according to BSE data.
Day 3 of Mukka Proteins' initial public offering (IPO) has seen 58.36 subscriptions from regular investors, 250.26 bookings from non-institutional investors (NII), and 189.28 bookings from qualified institutional buyers (QIB).
According to BSE data, at 17:18 IST, bids were received for 7,66,58,11,165 shares of the 5,60,00,435 shares that were offered in the Mukka Proteins IPO.
According to the red herring prospectus (RHP), the company plans to fund its working capital needs as well as general corporate objectives and an investment in Ento Proteins Private Limited, an associate. The net proceeds from the issuance will be used for these reasons.
Three of the promoter directors of the company are actively working in the business: Kalandan Mohammed Arif, Kalandan Mohammed Haris, and Kalandan Mohammed Althaf.
Fedex Securities Pvt Ltd is the book running lead manager for the Mukka Proteins IPO, while Cameo Corporate Services Limited is the registrar.
Based on the RHP, the listed peers of the company are Waterbase Ltd., Zeal Aqua Ltd., Godrej Agrovet Ltd., Avanti Feeds Ltd., and the latter has a P/E of 20.63.
Mukka Proteins Limited saw a rise in revenue of 52.52%, but an 84.07% decrease in profit after tax (PAT) between March 31, 2022, and March 31, 2023.
See Also: Mukka Proteins IPO: 10 Significant Risks from RHP to Take Into Account Before Investing
2.319.55-32.90 (-1.40%) BSE + Trade
Updated: 04 Mar 2024, 2366.00, 2310,00 DAY HIGH, 2,54,003 DAY LOW, Volume (NSE)
Currently, Mukka Proteins' IPO GMP
The grey market premium, or IPO GMP, for Mukka Proteins is +25. According to investorgain.com, this suggests that the share price of Mukka Proteins was selling at a premium of ₹25 on the black market.
The expected listing price of Mukka Proteins shares is indicated at ₹53 apiece, which is 89.29% more than the IPO price of ₹28. This is based on taking into account the upper end of the IPO pricing band and the present premium in the grey market.
The IPO GMP anticipates a robust listing based on the actions of the gray market over the last 28 sessions. Analysts at investorgain.com estimate that the lowest GMP is ₹0 and the highest GMP is ₹29.
A "grey market premium" denotes the willingness of investors to part with more money than the issue price.
See also: Mukka Proteins IPO sells out on day one, with strong demand in the retail sector. Verify GMP, the validity of your subscription, and more.
Review of Mukka Proteins' IPO by BP Wealth
The brokerage claims that the company has a history of steady growth in consolidated revenue from operations, with a 39.3% compound annual growth rate from FY21 to FY23. High obstacles to entry, consistent financial performance, and state-of-the-art products have all helped the brokerage to successfully oversee the company's expansion.
As we move forward, Mukka Proteins Ltd. offers a compelling investment opportunity in the fish protein sector thanks to its robust market position, varied product line, and international reach. Based on FY24 profits, the issue is fairly valued at a P/E of 9.3x on the higher price band. Therefore, we suggest giving the item a SUBSCRIBE rating," the brokerage stated.
Master Financial Services, Inc.
With a long 50-year history in the Indian marine industry, Mukka Proteins is a pioneer in the fishmeal industry, having founded one of the country's first steam-sterilized fishmeal mills, according to the brokerage. Fiscal 2023 is expected to see a massive increase in the industry's volume and value. The company's objective is to increase market share by meeting consumer demand for fish meal and fish oil. Value terms showed an on-year growth of 130–150%, while volume terms showed 90–110% growth.
The company, realizing the enormous potential and market for insect-based nutrition, has partnered with EPPL, a company that produces insect proteins, to manufacture and market insect meal and oil. The corporation wants to make it easier to enter new markets and increase its position in already-established export areas like China, Chile, and Japan. With a medium-to long-term outlook, investors are welcome to participate in this initial public offering (IPO), according to the brokerage.
Understanding the Mukka Proteins IPO:
Mukka Proteins IPO has been the talk of the town in financial circles lately. With an issue oversubscription of 136.89 times, it's evident that market sentiment towards this IPO is overwhelmingly positive. The strong participation from both NIIs and retail investors underscores the confidence in Mukka Proteins' business prospects. For those considering investing in this IPO, it's crucial to assess the Grey Market Premium (GMP), which serves as an indicator of market demand and potential listing gains.
Importance of Grey Market Premium (GMP):
The Grey Market Premium (GMP) is a crucial metric for investors eyeing IPOs. It reflects the difference between the IPO price and the price at which the shares are trading in the grey market before the official listing. A positive GMP indicates bullish sentiment among investors, suggesting potential listing gains. For the Mukka Proteins IPO, monitoring the GMP can provide valuable insights into investor appetite and expectations regarding the stock's performance post-listing.
Analyzing Investor Participation:
The significant oversubscription of the Mukka Proteins IPO, with the issue booked 136.89 times, highlights the robust interest from various investor categories. Non-Institutional Investors (NIIs), comprising high net-worth individuals and corporate bodies, have played a pivotal role in driving the subscription numbers. Additionally, retail investors, representing individual investors, have shown considerable enthusiasm towards this IPO. The widespread participation underscores the confidence in Mukka Proteins' growth prospects and the potential for strong returns.
Market Sentiment and Investor Confidence:
The overwhelming response to the Mukka Proteins IPO reflects positive market sentiment and investor confidence in the company's fundamentals. The strong demand from both institutional and retail investors indicates a belief in the company's growth trajectory and the value it offers to shareholders. As the bidding process draws to a close, all eyes are on the Grey Market Premium (GMP) to gauge market expectations and potential listing gains for investors.
Factors Driving Investor Interest:
Several factors have contributed to the heightened interest in the Mukka Proteins IPO. Firstly, the company's strong financial performance and growth prospects have attracted investors seeking exposure to the burgeoning protein market. Additionally, the management's track record and strategic initiatives have instilled confidence in the company's ability to deliver sustainable growth in the future. Moreover, the IPO frenzy in the market has also fuelled investor participation, with many eager to capitalize on potential listing gains.
Risks and Considerations:
While the Mukka Proteins IPO presents promising opportunities, investors must also consider the associated risks. Market volatility, regulatory changes, and industry dynamics can impact the company's performance and stock price post-listing. It's essential for investors to conduct thorough due diligence and assess their risk tolerance before participating in the IPO. Additionally, monitoring the Grey Market Premium (GMP) can provide insights into market sentiment and help investors make informed decisions.
Conclusion:
As the Mukka Proteins IPO approaches its final bidding day, the overwhelming response from investors underscores the optimism surrounding the company's prospects. With the issue booked 136.89 times so far, led by NIIs and retail investors, the IPO has generated significant buzz in the market. As investors await the listing, monitoring the Grey Market Premium (GMP) will be crucial in gauging market sentiment and potential listing gains. Whether you're a seasoned investor or a newcomer to the stock market, staying informed about developments in the IPO market can help you make sound investment decisions.
Tags:
Health